2016
DOI: 10.1172/jci82887
|View full text |Cite
|
Sign up to set email alerts
|

Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
43
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 54 publications
(46 citation statements)
references
References 49 publications
(53 reference statements)
3
43
0
Order By: Relevance
“…The mesenchymal marker VIMENTIN was upregulated in PDGFC-overexpressing HHIRSCs, a finding that supports the result from the cell proliferation assay showing increasing proliferation rates ( Figures 7B, C). As a factor in EGFR tyrosine kinase inhibitor resistance signaling, JAK1 is a molecule known to perturb skin hemostasis-related pathways and induce epidermal inflammation and downstream genes associated with clinical skin diseases (Jin et al, 2014;Jabbari et al, 2015;Yasuda et al, 2016). GJA1 encodes the gap junction protein connexin 43 (Cx43) in nearly every tissue in the body, and high expression leads to increased connexin density, which has been observed in the proximal bulb of the IRS (Flores et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…The mesenchymal marker VIMENTIN was upregulated in PDGFC-overexpressing HHIRSCs, a finding that supports the result from the cell proliferation assay showing increasing proliferation rates ( Figures 7B, C). As a factor in EGFR tyrosine kinase inhibitor resistance signaling, JAK1 is a molecule known to perturb skin hemostasis-related pathways and induce epidermal inflammation and downstream genes associated with clinical skin diseases (Jin et al, 2014;Jabbari et al, 2015;Yasuda et al, 2016). GJA1 encodes the gap junction protein connexin 43 (Cx43) in nearly every tissue in the body, and high expression leads to increased connexin density, which has been observed in the proximal bulb of the IRS (Flores et al, 2018).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, 2 recently developed mouse models with a Jak1 GoF mutation share a number of similarities with the human phenotype, including skin inflammation, activation of the IL-6-JAK-STAT pathway, liver and spleen abnormalities, and autoimmune disease. 3,8,9 Our observation that JAK1/2 inhibition with ruxolitinib resolved the severe dermatitis associated with the human JAK1 GoF mutation, combined with the mechanistic insights from mouse models, 8 provides further justification for targeting JAK1 in the treatment of atopic dermatitis.…”
Section: Jak1 Gain-of-function Causes An Autosomal Dominant Immune Dymentioning
confidence: 99%
“…Growing evidence suggests a benefit of targeting Janus kinase in AD (Guttman-Yassky et al, 2019). In these contexts, two N-ethyl-N-nitrosoureaederived models, CARMA-1/Card11-mutant mice (Jun et al, 2003) and JAK1 spade/spade mice (Yasuda et al, 2016) might be interesting models for understanding atopic inflammation from the immune signaling perspective.…”
Section: Genetically Engineered Modelsmentioning
confidence: 99%